Novo Nordisk remains coy over Wegovy blockbuster potential

Sales of Novo Nordisk’s newest obesity treatment, Wegovy, have been steadily increasing since its summer launch. Despite this, Novo CEO Lars Fruergaard Jørgensen remains silent on the drug’s blockbuster potential.
Lars Fruergaard Jørgensen, CEO of Novo Nordisk | Photo: Stine Bidstrup/ERH
Lars Fruergaard Jørgensen, CEO of Novo Nordisk | Photo: Stine Bidstrup/ERH
by christopher due karlsson, translated by daniel pedersen

With last Friday’s release of Novo Nordisk’s quarterly report for 2021, the pharmaceutical firm chose to reveal the actual sales figures for obesity drug Wegovy for the first time.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading